Skip to content
  • Contact Us
  • Shop
  • Login
  • Updates
  • Information Center
    • About OI
    • Navigating A New Diagnosis
    • Navigating Adult Health
    • OI Informational Factsheets
    • OIF Books and Brochures
    • Video Resources
      • OIF YouTube Channel
  • Resources
    • Impact Grant Program
    • OI Clinic Directory
    • Physician Directory
    • Support Networks
    • OIF Newsletters
    • Gemma’s Corner
    • Other Resources
  • Research
    • Join the OI Registry
    • Current OI Studies and Publications
    • Pain and OI Project
    • Rare Bone Disease Alliance
    • Rare Bone Disease TeleECHO Clinic Series
    • OI TeleEcho Clinic Series
    • Brittle Bone Disorders Consortium (BBDC)
    • Patient-Centered Outcomes Research (PCOR)
    • Events For Medical Professionals
  • Events
    • Upcoming Events
    • OIF Conferences
    • Events For Medical Professionals
  • Get Involved
    • Become a Member
    • Host a Fundraiser
    • Volunteer
  • About Us
    • Mission
    • Staff
    • Board of Directors
    • Medical Advisory Council
    • Financials
    • Policies and Bylaws
  • COIS
OI Canada
Donate

Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in OI

Posted on October 7, 2024 by OI Foundation

The OI Foundation would like to bring your attention to an update from Ultragenyx!

Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta

CLICK HERE TO VIEW THE PRESS RELEASE

Posted in Updates from the OIF
pag-1
nhc-1
nord-member-bw-2
rdcrn-logo-bw

© 2024 Osteogenesis Imperfecta Foundation

Privacy Policy